WallStSmart

AstraZeneca PLC (AZN)vsGeneral Dynamics Corporation (GD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 12% more annual revenue ($58.74B vs $52.55B). AZN leads profitability with a 17.4% profit margin vs 8.0%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48

GD

Buy

54

out of 100

Grade: C-

Growth: 6.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 6/9Altman Z: 2.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$183.40

$122.67 discount

UndervaluedFair: $306.07Overvalued
GDSignificantly Overvalued (-212.4%)

Margin of Safety

-212.4%

Fair Value

$114.87

Current Price

$352.50

$237.63 premium

UndervaluedFair: $114.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

GD1 strengths · Avg: 9.0/10
Market CapQuality
$95.31B9/10

Large-cap with strong market position

Areas to Watch

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

GD2 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.4%4/10

0.4% earnings growth

PEG RatioValuation
2.512/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bull Case : GD

The strongest argument for GD centers on Market Cap.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Bear Case : GD

The primary concerns for GD are EPS Growth, PEG Ratio.

Key Dynamics to Monitor

GD carries more volatility with a beta of 0.37 — expect wider price swings.

GD is growing revenue faster at 7.8% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (66/100 vs 54/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

General Dynamics Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

General Dynamics Corporation (GD) is an American aerospace and defense corporation. It is headquartered in Reston, Fairfax County, Virginia.

Visit Website →

Want to dig deeper into these stocks?